Literature DB >> 32542884

A clinical pathway for the management of Peyronie's disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association.

Eric Chung1,2, Michael Gillman3, John Tuckey4, Shane La Bianca5, Chris Love6.   

Abstract

OBJECTIVE: To provide a clinical framework and key guideline statements to assist clinicians in the evidence-based management of Peyronie's disease (PD).
METHODS: We conducted a review of the published literature relevant to PD management, with an emphasis on published clinical guidelines. References used in the text have been assessed according to their level of evidence, and guideline recommendations have been graded based on the Oxford Centre for Evidence-based Medicine Levels of Evidence.
RESULTS: The management of PD involves taking a detailed penile and sexual history, with a focused penile examination to identify plaque and hourglass deformity, and digital photographs of the erect curved (deformed) penis. Penile colour Duplex ultrasonography evaluates tunical plaque and underlying cavernosal smooth muscle and blood flow variables. The current therapy for PD can be divided into two main groups, namely, medical therapy and penile reconstructive surgery, and the patient should be counselled on the benefits and risks of each treatment option.
CONCLUSIONS: Peyronie's disease remains a clinical challenge and presents a considerable therapeutic dilemma as the current therapy addresses existing penile curvature only and is not very effective in preventing future penile fibrosis and/or reversing underlying erectile dysfunction.
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Peyronie's disease; clinical guideline; penile disorder; penile surgery; treatment outcomes

Year:  2020        PMID: 32542884     DOI: 10.1111/bju.15057

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  2 in total

1.  Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates.

Authors:  Eric Chung; Juan Wang
Journal:  Investig Clin Urol       Date:  2022-09

Review 2.  Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.

Authors:  Fuxun Zhang; Feng Qin; Jiuhong Yuan
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.